ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EPRX vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY

Eupraxia Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: EPRX 0 — MRK 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EPRX VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EPRX MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 20.70% -55.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield -5.98% 3.42% -9.40 MRK /fcf-yield <GO>
Operating Margin — 34.30% — TIE /operating-margins <GO>
Net Profit Margin — 28.10% — TIE /net-margins <GO>
Revenue Growth (YoY) — 1.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — 5.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.0 51.7 -2.70 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $477.8M $361.02B -$360.54B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EPRX REV MRK REV EPRX GROSS % MRK GROSS % EPRX FCF MRK FCF
FY 2025 $0 $65.01B — 74.8% -$28.6M $12.36B
FY 2024 $0 $64.17B — 76.3% -$30.0M $18.10B
FY 2023 $0 $60.12B — — -$20.7M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EPRX // BETA —
MRK // BETA 0.92